You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCMA-CD3 bispecific

Showing 1 - 25 of 721
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Canada, United States (PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 +

Active, not recruiting
  • Multiple Myeloma
  • PF-06863135 monotherapy IV or SC
  • +3 more
  • Encinitas, California
  • +37 more
Jul 7, 2022

Relapsed or Refractory Multiple Myeloma Trial in Nagoya, Shibuya-ku (Elranatamab (PF-06863135))

Active, not recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Nagoya, Aichi, Japan
  • +1 more
Jun 20, 2022

Multiple Myeloma Trial in Spain (REGN5458, Daratumumab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Athens, Greece
  • +8 more
Nov 30, 2022

Multiple Myeloma Trial (Linvoseltamab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 12, 2023

Elranatamab, Myeloma, Multiple Myeloma Trial in China (Elranatamab)

Recruiting
  • Elranatamab
  • +10 more
  • Fuzhou, Fujian, China
  • +18 more
Jan 18, 2023

Adult Patients Treated in Study R5459-RT-1944 Who Receive A

Not yet recruiting
  • Chronic Kidney Disease (CKD)
  • Noninterventional
  • (no location specified)
Nov 21, 2022

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023

Chronic Kidney Disease (CKD) Trial in New Haven, New York, Philadelphia (REGN5459, REGN5458)

Not yet recruiting
  • Chronic Kidney Disease (CKD)
  • New York, New York
    New York University Langone Health - Transplant Institute
Jul 11, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)

Active, not recruiting
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Indianapolis, Indiana
  • +6 more
Aug 16, 2022

Hematologic Malignancies Trial in Japan (Teclistamab)

Recruiting
  • Hematologic Malignancies
  • Chiba, Japan
  • +14 more
Aug 11, 2022

Colorectal Cancer Trial (Administration of CC-3)

Not yet recruiting
  • Colorectal Cancer
  • Administration of CC-3
  • (no location specified)
Aug 11, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))

Active, not recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +75 more
Oct 4, 2022

POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

Active, not recruiting
  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome
  • anti-CD19/BCMA CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 5, 2021

Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)

Not yet recruiting
  • Advanced Prostate Cancer
  • Lyon, France
  • +2 more
Oct 18, 2023

AML, Childhood Trial in United States (CD33*CD3 BsAb)

Active, not recruiting
  • AML, Childhood
  • CD33*CD3 BsAb
  • Birmingham, Alabama
  • +12 more
Jan 12, 2023

Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)

Not yet recruiting
  • Malignant Glioma
  • Glioblastoma
  • hEGFRvIII-CD3 (BRiTE)
  • Activated Cell Therapy
  • Durham, North Carolina
    Duke University Medical Center
Jun 24, 2022

Multiple Myeloma Trial (Elranatamab (PF-06863135))

Temporarily not available
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • (no location specified)
Jul 15, 2022

Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

Withdrawn
  • Leukemia
  • Stem Cell Transplantation
  • Munich, Bavaria, Germany
    3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)

Recruiting
  • Large B-cell Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 21, 2022

Multiple Myeloma Trial in Worldwide (REGN5458)

Recruiting
  • Multiple Myeloma
  • Miami, Florida
  • +26 more
Aug 16, 2022

Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (AZD5863)

Recruiting
  • Gastric Cancer
  • +3 more
  • Jacksonville, Florida
  • +16 more
Aug 17, 2023

Medicine Called Elranatamab in People With Relapsed Refractory

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jun 30, 2023